Valuation: Hemostemix Inc.

Market Cap 10.88M 7.67M 6.72M 6.2M 5.8M 723M 11.11M 74.49M 28.82M 358M 28.79M 28.17M 1.24B P/E 2024
-4.36x
P/E 2025 -3.12x
Enterprise Value 13.74M 9.68M 8.49M 7.83M 7.33M 914M 14.03M 94.08M 36.4M 452M 36.37M 35.57M 1.57B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
82.24%
Yield 2024 *
-
Yield 2025 -
1 day+10.00%
1 week+10.00%
3 months-15.38%
6 months-35.29%
Current year-38.89%
1 month 0.05
Extreme 0.05
0.06
Current year 0.04
Extreme 0.04
0.11
1 year 0.04
Extreme 0.04
0.16
3 years 0.04
Extreme 0.035
0.42
5 years 0.04
Extreme 0.035
0.42
10 years 0
Extreme 0
5.9
Manager TitleAgeSince
Chief Executive Officer - 10/02/2020
Director of Finance/CFO - 05/03/2020
Chief Tech/Sci/R&D Officer - 14/10/2021
Director TitleAgeSince
Chairman 69 11/03/2020
Director/Board Member 67 09/02/2020
Director/Board Member - 26/11/2019
Date Insider Type Main position Quantity % Market Cap.
12-18Option

Director

65,000 0.0345%
12-16Option

Founder

242,000 0.1284%
12-16Buy

Founder

20,000 0.0106%
Change 5-day change 1-year change 3-year change Capi.($)
+10.00%+10.00%-59.26%-52.17% 7.67M
+0.13%-1.33%+67.18%+121.93% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+1.64%+2.91%-12.83%-13.26% 23.07B
-0.18%+5.02%+2.90%+409.62% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+3.81%+30.68%-32.21% 15.94B
+0.47%+6.95%+24.61%+189.66% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +4.12%+6.15%+37.61%+115.45% 22.63B
Weighted average by Cap. +3.22%+7.62%+54.60%+127.44%

Financials

2024 2025
Net sales - -
Net income -2.62M -1.84M -1.62M -1.49M -1.4M -174M -2.67M -17.91M -6.93M -85.97M -6.92M -6.77M -298M -4.71M -3.32M -2.91M -2.69M -2.51M -313M -4.81M -32.27M -12.49M -155M -12.48M -12.2M -537M
Net Debt 4.23M 2.98M 2.61M 2.41M 2.26M 281M 4.32M 28.97M 11.21M 139M 11.2M 10.95M 482M 2.86M 2.02M 1.77M 1.63M 1.53M 190M 2.92M 19.59M 7.58M 94M 7.57M 7.41M 326M
Logo Hemostemix Inc.
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Employees
-
Date Price Change Volume
22/06/26 CA$0.0550 +10.00% 5,500